SCHEMBL9890773

SCHEMBL9890773

CNC(=O)Cc1cc(F)ccc1-c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.44
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
KCNH2 Q12809 1/20 0.43
KCNA3 P22001 2/20 0.42
SHMT1 P34896 1/20 0.42
ANO1 Q5XXA6 4/20 0.40
ANO2 Q9NQ90 1/20 0.40
POLB P06746 2/20 0.40
P2RX7 Q99572 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
TP53 P04637 2/20 0.38
THRB P10828 1/20 0.38
GCGR P47871 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890771 0.92 SHMT1 (0.47) CNR1KCNA3SHMT1ANO1TP53
SCHEMBL2393668 0.91 KCNA5 (0.41) SLC6A4SHMT1POLBLMNAALDH1A1
SCHEMBL2396004 0.86 FFAR1 (0.46) HTR2ASLC6A4P2RX7LMNAMAPT
SCHEMBL9890779 0.84 ALDH1A1 (0.44) SLC6A4ANO1POLBALDH1A1CYP1A2
SCHEMBL9890777 0.84 PSEN1 (0.46) GCGR
SCHEMBL9892693 0.83 PTGDR2 (0.48) HTR2ASLC6A4KCNH2ANO1LMNA
SCHEMBL3736882 0.82 AKR1C3 (0.49) ANO1ANO2
SCHEMBL9890775 0.82 SMN1; SMN2 (0.46) KCNH2SHMT1ANO1LMNACHRM3
SCHEMBL9890772 0.81 CYP2C19 (0.45) CNR1KCNA3ANO1ANO2CYP2C19
SCHEMBL9890782 0.80 PSEN1 (0.45) P2RX7LMNAMAPTGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CNR1 221/4885HTR2A 600/4885SLC6A4 932/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 CNR1 221/4885HTR2A 600/4885SLC6A4 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.